{"organizations": [], "uuid": "9af0433c003930b1d7f32b183f48961196451cc0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s3.reutersmedia.net/resources/r/?d=20180416&i=OV8BOINPN&w=1200&r=OV8BOINPN&t=2", "site_section": "http://feeds.reuters.com/reuters/UKVideoLatest", "section_title": "Reuters Video: Latest Videos UK", "url": "https://uk.reuters.com/video/2018/04/16/shire-sells-cancer-drugs-to-servier-as-t?videoId=418335716", "country": "US", "domain_rank": 408, "title": "Shire sells cancer drugs to Servier as Takeda circles", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T15:52:00.000+03:00", "replies_count": 0, "uuid": "9af0433c003930b1d7f32b183f48961196451cc0"}, "author": "", "url": "https://uk.reuters.com/video/2018/04/16/shire-sells-cancer-drugs-to-servier-as-t?videoId=418335716", "ord_in_thread": 0, "title": "Shire sells cancer drugs to Servier as Takeda circles", "locations": [], "entities": {"persons": [{"name": "shire", "sentiment": "negative"}, {"name": "takeda", "sentiment": "negative"}, {"name": "pascale davies", "sentiment": "none"}], "locations": [{"name": "japan", "sentiment": "none"}], "organizations": [{"name": "bst", "sentiment": "negative"}, {"name": "shire", "sentiment": "negative"}, {"name": "servier", "sentiment": "negative"}, {"name": "takeda pharmaceutical", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Shire sells cancer drugs to Servier as Takeda circles 1:52pm BST - 01:20 \nShire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. As Pascale Davies reports, the deal suggests there is value locked up within Shire's portfolio - despite a dismal share price performance in the past two years.   \nShire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. As Pascale Davies reports, the deal suggests there is value locked up within Shire's portfolio - despite a dismal share price performance in the past two years.  //reut.rs/2qACHjH", "external_links": [], "published": "2018-04-16T15:52:00.000+03:00", "crawled": "2018-04-16T16:23:03.002+03:00", "highlightTitle": ""}